Download MendeleyDevelopment of autotaxin inhibitors: A series of tetrazole cinnamides.
Thomson, C.G., Le Grand, D., Dowling, M., Beattie, D., Elphick, L., Faller, M., Freeman, M., Hardaker, E., Head, V., Hemmig, R., Hill, J., Lister, A., Pascoe, D., Rieffel, S., Shrestha, B., Steward, O., Zink, F.(2021) Bioorg Med Chem Lett 31: 127663-127663
- PubMed: 33160025
- DOI: https://doi.org/10.1016/j.bmcl.2020.127663
- Primary Citation of Related Structures:
6Y5M - PubMed Abstract:
A series of inhibitors of Autotaxin (ATX) have been developed from a high throughput screening hit, 1a, which shows an alternative binding mode to known catalytic site inhibitors. Selectivity over the hERG channel and microsomal clearance were dependent on the lipophilicity of the compounds, and this was optimised by reduction of clogD whilst maintaining high affinity ATX inhibition. Compound 15a shows good oral exposure, and concentration dependent inhibition of formation of LPA in vivo, as shown in pharmacokinetic-pharmacodynamic (PK/PD) experiments.
Organizational Affiliation:
Global Discovery Chemistry, Novartis Institutes For Biomedical Research, Horsham, UK. Electronic address: chris.thomson@pharmaron-uk.com.
